Journal
NEUROLOGY
Volume 79, Issue 20, Pages 2044-2049Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3182749eed
Keywords
-
Categories
Funding
- NIH
- National Headache Foundation
- Migraine Research Fund
- CogniMed
- Scientiae
- Intramed
- SAGE Publishing
- Lippincott Williams Wilkins
- Oxford University Press
- Cambridge University Press
- Miller Medical
- Annenberg for Health Sciences
- Advanced Neurostimulation Systems
- Boston Scientific
- St Jude Medical, Inc.
- Medtronic
- National Institute of Neurological Disorders and Stroke/NIH
- Mayo Clinic
- AGA
- Capnia
- MAP
- Nu Pathe Merck
- GSK
- Eli Lilly
- GlaxoSmithKline
- Merck
- Allergan
- Cypress
- ANS
- MAP Pharma
- Depomed
- XLT
- Schwartz
- NuPathe
- Advanced Bionics
- Alexza
- MAP Pharmaceuticals
- Ortho-McNeil
- Neuralieve
- Takeda
- MSD
- Johnson Johnson
- eNeura
- Almirall
- ATI
- BMS
- Boehringer
- Coherex
- Colucid
- Lilly
- Minster
- NeurAxon
- NTP
- Pfizer
- International Headache Society
- Lundbeck Foundation
- Foundation of Ulla, Mogens Folmer Andersen
- Laegernes Forsikringsforening af 1891
Ask authors/readers for more resources
Objectives: Migraine aura is commonly considered to be a distinct phase of a migraine attack that precedes headache. The objective of the study was to examine a large number of prospectively recorded attacks of migraine with aura and determine the timing of headache and other migraine symptoms relative to aura. Methods: As part of a clinical trial we collected prospective data on the time course of headache and other symptoms relative to the aura. Patients (n = 267) were enrolled from 16 centers, and asked to keep a headache diary for 1 month (phase I). They were asked to record headache symptoms as soon as possible after aura began and always within 1 hour of aura onset. A total of 456 attacks were reported during phase I by 201 patients. These patients were then randomized and included in phase II, during which a total of 405 attacks were reported in 164 patients. In total, we present data from 861 attacks of migraine with aura from 201 patients. Results: During the aura phase, the majority of attacks (73%) were associated with headache. Other migraine symptoms were also frequently reported during the aura: nausea (51%), photophobia (88%), and photophobia (73%). During the first 15 minutes within the onset of aura, 54% of patients reported headache fulfilling the criteria for migraine. Conclusion: Our results indicate that headaches as well as associated migraine symptoms are present early, during the aura phase of the migraine attack in the majority of patients. Neurology (R) 2012; 79: 2044-2049
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available